Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
NLSPW
Upturn stock ratingUpturn stock rating

NLS Pharmaceutics AG (NLSPW)

Upturn stock ratingUpturn stock rating
$0.02
Last Close (24-hour delay)
Profit since last BUY0%
upturn advisory
WEAK BUY
BUY since 9 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: NLSPW (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $0

1 Year Target Price $0

Analysts Price Target For last 52 week
$0Target price
Low$
Current$0.02
high$

Analysis of Past Performance

Type Stock
Historic Profit -80%
Avg. Invested days 9
Today’s Advisory WEAK BUY
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 37.77M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta 0.04
52 Weeks Range 0.00 - 0.06
Updated Date 05/31/2025
52 Weeks Range 0.00 - 0.06
Updated Date 05/31/2025
Dividends yield (FY) -
Basic EPS (TTM) -

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -111.41%
Return on Equity (TTM) -

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 1687887
Shares Outstanding -
Shares Floating 1687887
Percent Insiders -
Percent Institutions -

Analyst Ratings

Rating -
Target Price -
Buy -
Strong Buy -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

NLS Pharmaceutics AG

stock logo

Company Overview

overview logo History and Background

NLS Pharmaceutics AG, founded in 2015, is a Swiss biopharmaceutical company focused on developing and commercializing innovative therapies for patients with rare and complex central nervous system disorders.

business area logo Core Business Areas

  • Quilience (mazindol ER): NLS Pharmaceutics' primary focus is on the development and commercialization of Quilience, an extended-release formulation of mazindol. It is being developed for the treatment of narcolepsy. Other indications being explored include ADHD.

leadership logo Leadership and Structure

The leadership team includes key executives in areas such as clinical development, regulatory affairs, and finance. Organizational structure is typical of a small biopharmaceutical company.

Top Products and Market Share

overview logo Key Offerings

  • Quilience (mazindol ER): Quilience is an extended-release formulation of mazindol being developed for narcolepsy and ADHD. Market share data is currently unavailable as it is not yet approved for sale. Competitors include stimulant and non-stimulant medications from companies like Jazz Pharmaceuticals and Takeda Pharmaceutical.

Market Dynamics

industry overview logo Industry Overview

The CNS disorder market is characterized by significant unmet needs and growing patient populations, driving demand for novel therapies.

Positioning

NLS Pharmaceutics aims to address unmet needs in narcolepsy and ADHD with Quilience, offering a potentially differentiated treatment option.

Total Addressable Market (TAM)

The TAM for narcolepsy and ADHD is substantial, estimated in the billions of dollars globally. NLS Pharmaceutics' positioning hinges on successful clinical trials and market access for Quilience.

Upturn SWOT Analysis

Strengths

  • Novel formulation of mazindol (Quilience)
  • Focus on unmet needs in CNS disorders
  • Experienced management team

Weaknesses

  • Limited financial resources
  • Single product pipeline (Quilience)
  • Regulatory approval risks

Opportunities

  • Successful clinical trial outcomes
  • Strategic partnerships
  • Expansion into new indications

Threats

  • Competition from established players
  • Regulatory hurdles
  • Clinical trial failures

Competitors and Market Share

competitor logo Key Competitors

  • JAZZ
  • TAK

Competitive Landscape

NLS Pharmaceutics faces intense competition from established pharmaceutical companies with marketed products for narcolepsy and ADHD. Its advantage depends on demonstrating superior efficacy and safety with Quilience.

Growth Trajectory and Initiatives

Historical Growth: Growth is primarily driven by clinical development progress.

Future Projections: Future growth depends on successful clinical trials, regulatory approval, and commercialization of Quilience.

Recent Initiatives: Recent initiatives include advancing clinical trials for Quilience and seeking strategic partnerships.

Summary

NLS Pharmaceutics is a small biopharmaceutical company focused on developing Quilience for CNS disorders. Success hinges on clinical trial outcomes and regulatory approval. The company faces significant competition and financial risks, but it has the potential to address unmet needs in the narcolepsy and ADHD markets. They need to look out for any adverse regulatory decisions on products in their pipeline.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Analyst Reports (where available)

Disclaimers:

This analysis is based on publicly available information and is not financial advice. Investing in pharmaceutical companies is inherently risky, and investors should conduct their own due diligence.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About NLS Pharmaceutics AG

Exchange NASDAQ
Headquaters -
IPO Launch date 2021-01-29
Co-Founder, CEO & Director Mr. Alexander Zwyer M.B.A.
Sector Healthcare
Industry Biotechnology
Full time employees -
Full time employees -

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience for the treatment of narcolepsy; and Nolazol for the treatment of ADHD. The company also develops NLS-4, a selective dopamine reuptake inhibitor treatment for the chronic fatigue associated with the symptoms of Long-COVID; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist for improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. It has licensing agreements with Pegasus Advanced Research for use of mazindol for the treatment of ADHD. NLS Pharmaceutics AG was incorporated in 2015 and is headquartered in Zurich, Switzerland.